Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung
Cancer Res Treat. 2017;49(2):423-429.   Published online 2016 Aug 3     DOI: https://doi.org/10.4143/crt.2016.191
Citations to this article as recorded by Crossref logo
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
Yu-Ju Lin, Chun-Nan Kuo, Yu Ko
The Breast.2021; 57: 18.     CrossRef
Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung, Chin-Yao Lin
Medicine.2021; 100(47): e27859.     CrossRef
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
The Breast.2020; 54: 121.     CrossRef
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
Breast Cancer Research and Treatment.2018; 170(3): 583.     CrossRef
Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2018; 128: 110.     CrossRef
Angiomodulators in cancer therapy: New perspectives
Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Büsselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak
Biomedicine & Pharmacotherapy.2017; 89: 578.     CrossRef
Eribulin in advanced breast cancer: safety, efficacy and new perspectives
Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco C Merlano
Future Oncology.2017; 13(30): 2759.     CrossRef
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
Oncotarget.2017; 8(67): 112076.     CrossRef